Clinical Trials - malecare.org

Dendreon Has Three Posters At ASCO That Add New And Great News For Men With Advanced Prostate Cancer

The American Society of Clinical Oncologists (ASCO) posted on Wednesday the abstracts from the Genitourinary Conference which is scheduled for February 2-4 in San Francisco, California. Dendreon, the creator of the immunotherapy Provenge for men with metastatic castrate resistant advanced prostate cancer has three very interesting and informative posters which will appear at the conference. [...]

By Malecare|2021-02-17T11:03:31-05:00February 3rd, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, Provenge, Research, Uncategorized, vaccines|0 Comments

Announcing A Compassionate Use Trial of Alpharadin

Radium-223 choride, also known as Alpharadin, has demonstrated a small but statistically significant survival benefit in men with symptomatic metastatic castrate resistant prostate cancer (mCRPC). My expectation is that it will be approved by the FDA some time later this year. Additionally, my hope is that it will also be approved Europe. To read more [...]

By Malecare|2020-02-04T10:11:16-05:00February 2nd, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Uncategorized|0 Comments

REVLIMID FAILS TO EXTEND SURVIVAL IN ADVANCED PROSTATE CANCER

The late-stage trial of Revlimid (lenalidomide) for the treatment of advanced prostate cancer has been discontinued after preliminary data shows that it does not extend survival! The independent monitoring committee recommended that the pivotal Phase III Mainsail trial be halted after it determined that adding Revlimid to standard treatments would not significantly increase the overall [...]

By Malecare|2012-01-31T12:01:35-05:00January 31st, 2012|2nd line hormone therapy, Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Revlimid (lenalidomide), Uncategorized, Understanding APC|0 Comments

OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium

Maybe we are about to have another new treatment for advanced prostate cancer that will earn the coveted descriptor, “ON THE HORIZON.” OncoGenex Pharmaceuticals Inc. (OGXI) has said that they will be presenting preliminary data from their phase 2 trials evaluating their investigational compound OGX-427, in prostate and bladder cancer. The data will be presented [...]

By Malecare|2020-02-04T11:46:20-05:00January 23rd, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, OGX-427, On The Horizon, Uncategorized|0 Comments

The Value of Evaluating Circulating Tumor Cells – Better Survival Predictions

The use of the PSA as a prostate cancer screening tool has been a controversial issue for many years. Within the last year the issue has again come to the forefront of the public awareness, especially because of the recent move of the U.S Preventative Task Force to discourage using the PSA as a screening [...]

By Malecare|2017-10-19T10:51:32-04:00January 18th, 2012|abiraterone acetate, Advanced Prostate Cancer, Clinical Trials, Clinical Trials, CTCs, General Information, Research, Uncategorized, Understanding APC|1 Comment